During treated HIV infection, immune activation and biomarkers of inflammation improve within the first years, but residual immune activation may persist [7,20], with high CD8+ T-cell count and low CD4/CD8 ratio [21,22]. The gene discussed is CD4; the disease is HIV infectious disease.